Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis

Emily E. Brown, Yi Zhen Joan Lee, Marc K Halushka, Charles Jr Steenbergen, Nicole M. Johnson, Johana Almansa, Ryan J. Tedford, Oscar Cingolani, Stuart D. Russell, Kavita Sharma, Daniel P. Judge

Research output: Contribution to journalArticle

Abstract

Amyloidosis is a group of conditions characterized by the accumulation of amyloid deposits in various tissues. Among these disorders, ATTR amyloidosis occurs either with or without a TTR pathogenic variant. Treatment for amyloidosis depends on the subtype, which is often identified through a tissue biopsy followed by liquid chromatography tandem mass spectrometry (LC–MS/MS). Genetic testing may be done to confirm these results for patients with ATTR amyloidosis; however, the necessity of genetic testing after LC–MS/MS has not been evaluated. A retrospective review identified 153 patients diagnosed with biopsy-proven ATTR amyloidosis, and 56 of these patients underwent both genetic testing and LC–MS/MS. LC–MS/MS and proteomics correctly reported the mutant peptide and heterozygosity in 47/56 (84%) cases. It failed to identify two individuals who were homozygous for the ATTRV122I mutation and failed to detect the following mutations in six other individuals: ATTRA19D, ATTRF44L, ATTRT60A, ATTRI68L and ATTRV122I. Therefore, LC–MS/MS is not sufficient to rule out a pathogenic mutation in cases of ATTR amyloid, and genetic testing should be performed in most cases of ATTR amyloidosis. Correct recognition of hereditary ATTR amyloidosis is important for estimating prognosis, proper familial counselling and guiding use of therapies, such as liver transplantation.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalAmyloid
DOIs
StateAccepted/In press - May 11 2017

Fingerprint

Prealbumin
Genetic Testing
Amyloidosis
Amyloid
Mutation
Familial Amyloidosis
Biopsy
Amyloid Plaques
Tandem Mass Spectrometry
Liquid Chromatography
Liver Transplantation
Proteomics
Counseling
Peptides
Therapeutics

Keywords

  • genetic testing
  • mass spectrometry
  • Transthyretin amyloidosis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. / Brown, Emily E.; Lee, Yi Zhen Joan; Halushka, Marc K; Steenbergen, Charles Jr; Johnson, Nicole M.; Almansa, Johana; Tedford, Ryan J.; Cingolani, Oscar; Russell, Stuart D.; Sharma, Kavita; Judge, Daniel P.

In: Amyloid, 11.05.2017, p. 1-4.

Research output: Contribution to journalArticle

Brown, Emily E. ; Lee, Yi Zhen Joan ; Halushka, Marc K ; Steenbergen, Charles Jr ; Johnson, Nicole M. ; Almansa, Johana ; Tedford, Ryan J. ; Cingolani, Oscar ; Russell, Stuart D. ; Sharma, Kavita ; Judge, Daniel P. / Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. In: Amyloid. 2017 ; pp. 1-4.
@article{bb66c6ecfeda4f6abc0f8dec633c20e9,
title = "Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis",
abstract = "Amyloidosis is a group of conditions characterized by the accumulation of amyloid deposits in various tissues. Among these disorders, ATTR amyloidosis occurs either with or without a TTR pathogenic variant. Treatment for amyloidosis depends on the subtype, which is often identified through a tissue biopsy followed by liquid chromatography tandem mass spectrometry (LC–MS/MS). Genetic testing may be done to confirm these results for patients with ATTR amyloidosis; however, the necessity of genetic testing after LC–MS/MS has not been evaluated. A retrospective review identified 153 patients diagnosed with biopsy-proven ATTR amyloidosis, and 56 of these patients underwent both genetic testing and LC–MS/MS. LC–MS/MS and proteomics correctly reported the mutant peptide and heterozygosity in 47/56 (84{\%}) cases. It failed to identify two individuals who were homozygous for the ATTRV122I mutation and failed to detect the following mutations in six other individuals: ATTRA19D, ATTRF44L, ATTRT60A, ATTRI68L and ATTRV122I. Therefore, LC–MS/MS is not sufficient to rule out a pathogenic mutation in cases of ATTR amyloid, and genetic testing should be performed in most cases of ATTR amyloidosis. Correct recognition of hereditary ATTR amyloidosis is important for estimating prognosis, proper familial counselling and guiding use of therapies, such as liver transplantation.",
keywords = "genetic testing, mass spectrometry, Transthyretin amyloidosis",
author = "Brown, {Emily E.} and Lee, {Yi Zhen Joan} and Halushka, {Marc K} and Steenbergen, {Charles Jr} and Johnson, {Nicole M.} and Johana Almansa and Tedford, {Ryan J.} and Oscar Cingolani and Russell, {Stuart D.} and Kavita Sharma and Judge, {Daniel P.}",
year = "2017",
month = "5",
day = "11",
doi = "10.1080/13506129.2017.1324418",
language = "English (US)",
pages = "1--4",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis

AU - Brown, Emily E.

AU - Lee, Yi Zhen Joan

AU - Halushka, Marc K

AU - Steenbergen, Charles Jr

AU - Johnson, Nicole M.

AU - Almansa, Johana

AU - Tedford, Ryan J.

AU - Cingolani, Oscar

AU - Russell, Stuart D.

AU - Sharma, Kavita

AU - Judge, Daniel P.

PY - 2017/5/11

Y1 - 2017/5/11

N2 - Amyloidosis is a group of conditions characterized by the accumulation of amyloid deposits in various tissues. Among these disorders, ATTR amyloidosis occurs either with or without a TTR pathogenic variant. Treatment for amyloidosis depends on the subtype, which is often identified through a tissue biopsy followed by liquid chromatography tandem mass spectrometry (LC–MS/MS). Genetic testing may be done to confirm these results for patients with ATTR amyloidosis; however, the necessity of genetic testing after LC–MS/MS has not been evaluated. A retrospective review identified 153 patients diagnosed with biopsy-proven ATTR amyloidosis, and 56 of these patients underwent both genetic testing and LC–MS/MS. LC–MS/MS and proteomics correctly reported the mutant peptide and heterozygosity in 47/56 (84%) cases. It failed to identify two individuals who were homozygous for the ATTRV122I mutation and failed to detect the following mutations in six other individuals: ATTRA19D, ATTRF44L, ATTRT60A, ATTRI68L and ATTRV122I. Therefore, LC–MS/MS is not sufficient to rule out a pathogenic mutation in cases of ATTR amyloid, and genetic testing should be performed in most cases of ATTR amyloidosis. Correct recognition of hereditary ATTR amyloidosis is important for estimating prognosis, proper familial counselling and guiding use of therapies, such as liver transplantation.

AB - Amyloidosis is a group of conditions characterized by the accumulation of amyloid deposits in various tissues. Among these disorders, ATTR amyloidosis occurs either with or without a TTR pathogenic variant. Treatment for amyloidosis depends on the subtype, which is often identified through a tissue biopsy followed by liquid chromatography tandem mass spectrometry (LC–MS/MS). Genetic testing may be done to confirm these results for patients with ATTR amyloidosis; however, the necessity of genetic testing after LC–MS/MS has not been evaluated. A retrospective review identified 153 patients diagnosed with biopsy-proven ATTR amyloidosis, and 56 of these patients underwent both genetic testing and LC–MS/MS. LC–MS/MS and proteomics correctly reported the mutant peptide and heterozygosity in 47/56 (84%) cases. It failed to identify two individuals who were homozygous for the ATTRV122I mutation and failed to detect the following mutations in six other individuals: ATTRA19D, ATTRF44L, ATTRT60A, ATTRI68L and ATTRV122I. Therefore, LC–MS/MS is not sufficient to rule out a pathogenic mutation in cases of ATTR amyloid, and genetic testing should be performed in most cases of ATTR amyloidosis. Correct recognition of hereditary ATTR amyloidosis is important for estimating prognosis, proper familial counselling and guiding use of therapies, such as liver transplantation.

KW - genetic testing

KW - mass spectrometry

KW - Transthyretin amyloidosis

UR - http://www.scopus.com/inward/record.url?scp=85019253910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019253910&partnerID=8YFLogxK

U2 - 10.1080/13506129.2017.1324418

DO - 10.1080/13506129.2017.1324418

M3 - Article

SP - 1

EP - 4

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

ER -